Cosmos Study November 13, 2025 Dual-Team Study Team A:Kersten Bartelt, RNDan GreerEmily Higgs Team B:Louis Kazaglis, MDTed Stamp Key Findings Among patients with polycystic ovary syndrome (PCOS), the median one-year weight change was an 11.5% loss for those treated with a GLP-1, compared to a 1.9% loss among those treated with metformin
Overall, we observed more significantly downregulated genes in response to albumin at 0.5 hpi and 3 hpi, while the amount of significantly up- and downregulated genes was more balanced following prolonged infection (Supplementary Fig
Dose changes should not be made by guesswork, social media advice, or another patients experience
What should I do if my medication looks cloudy
This mechanism is particularly relevant for patients with HFpEF, as demonstrated by the STEP-HFpEF trial, which showed that semaglutide significantly improved heart failure symptoms, functional capacity, and weight reduction in obese HFpEF patients.84 These findings emphasize the potential of GLP-1 receptor agonists as a cornerstone therapy in managing CMS, addressing metabolic dysfunction, CVD, and heart failure simultaneously
Choose the comprehensive path to health and well-being